STOCK TITAN

Edwards Lifesciences (EW) CVP exercises 13,457 performance shares with 7,469 withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp corporate officer Donald E. Bobo Jr. reported equity compensation activity tied to performance-based restricted stock units. On May 11, 2026, he exercised 13,457 Performance Rights, receiving the same number of shares of common stock.

To cover tax obligations, 7,469 common shares were withheld at $79.96 per share, a non-market disposition. After these transactions, he held 40,235.2532 common shares directly, plus 121,756 shares by trust and 38,969.5756 shares in a 401(k) indirectly. A prior grant from May 11, 2023 vested at 167.70% of its target following a three-year performance period, and the related Performance Rights now show 0 remaining, having been fully exercised.

Positive

  • None.

Negative

  • None.
Insider BOBO DONALD E JR
Role CVP,Strategy/Corp Development
Type Security Shares Price Value
Exercise Performance Rights 13,457 $0.00 --
Exercise Common Stock 13,457 $0.00 --
Tax Withholding Common Stock 7,469 $79.96 $597K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Performance Rights — 0 shares (Direct, null); Common Stock — 40,235.253 shares (Direct, null); Common Stock — 38,969.576 shares (Indirect, 401(k))
Footnotes (1)
  1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030.
Performance Rights exercised 13,457 shares Converted into common stock on May 11, 2026
Shares withheld for taxes 7,469 shares at $79.96 Tax-withholding disposition on May 11, 2026
Direct common shares after transactions 40,235.2532 shares Direct ownership following exercise and withholding
Indirect trust holdings 121,756 shares Common stock held indirectly by trust
Indirect 401(k) holdings 38,969.5756 shares Common stock held through 401(k) plan
Vesting percentage of target RSUs 167.70% Performance-based units vesting as of May 11, 2026
Remaining Performance Rights 0.0000 units Balance after exercise of 13,457 units
restricted stock units financial
"granted a target number of shares covered by restricted stock units with performance-based vesting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance-based vesting requirements financial
"restricted stock units with performance-based vesting requirements over a three-year performance period"
Performance Rights financial
"These Performance Rights expire on May 10, 2030."
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
401(k) financial
"total_shares_following_transaction":"38969.5756","direct_or_indirect":"I","nature_of_ownership":"401(k)""
A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOBO DONALD E JR

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CVP,Strategy/Corp Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/11/2026M13,457(1)A$0(1)40,235.2532D
Common Stock05/11/2026F7,469D$79.9632,766.2532D
Common Stock38,969.5756I401(k)
Common Stock121,756IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Rights(1)05/11/2026M13,45705/11/2026 (2)Common Stock13,457$0.00000.0000D
Explanation of Responses:
1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
2. These Performance Rights expire on May 10, 2030.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edwards Lifesciences (EW) executive Donald Bobo Jr. report in this Form 4?

Donald E. Bobo Jr. reported the exercise of 13,457 Performance Rights into common stock and a related tax-withholding disposition of 7,469 shares at $79.96 per share. These transactions reflect equity compensation activity rather than open-market buying or selling.

How many Edwards Lifesciences (EW) shares does Donald Bobo Jr. hold after this filing?

After the reported transactions, Donald Bobo Jr. holds 40,235.2532 Edwards Lifesciences common shares directly, 121,756 shares indirectly through a trust, and 38,969.5756 shares indirectly via a 401(k). These figures show his combined post-transaction equity exposure reported in this Form 4.

What was the size and nature of the tax withholding in the Edwards Lifesciences (EW) Form 4?

The filing shows 7,469 Edwards Lifesciences common shares withheld at $79.96 per share to satisfy tax obligations. This F-code transaction is a non-market disposition typically associated with vesting or exercise of equity awards, not an open-market sale decision.

What performance-based equity grant is referenced in this Edwards Lifesciences (EW) Form 4?

The Form 4 references a grant of restricted stock units with performance-based vesting made on May 11, 2023. After a three-year performance period, the board’s committee determined 167.70% of the target shares would vest as of May 11, 2026, and those vested shares are reflected here.

Are any Performance Rights still outstanding for Donald Bobo Jr. at Edwards Lifesciences (EW)?

The filing shows 13,457 Performance Rights exercised into common stock, leaving a remaining balance of 0.0000 Performance Rights. A footnote states these Performance Rights were scheduled to expire on May 10, 2030, but they have now been fully exercised and reported.